Dayton Children’s Hospital Taps Medline as Laboratory Prime Vendor

Agreement follows company’s supply chain solutions during the pandemic

Medline has been selected as Dayton Children’s Hospital’s laboratory prime vendor, entering into a multi-year agreement; an expansion of an existing partnership. For more than eight years, Medline has provided surgical and medical supplies to Dayton Children’s Hospital.

During the pandemic, Medline expanded its role with Dayton Children’s Hospital, helping the procurement team to improve supply chain and product standardization. Solutions included integrating laboratory supply procurement with the hospital’s broader supply chain operations, providing the hospital with a greater understanding of supply needs and available products, as well as potential product substitutions. As a result, the hospital was able to provide optimal care during the pandemic, as well as laboratory services and testing kits to other area hospitals and community residents.

“Because we were in constant communication with Medline, we were confident in our ability to maintain our supplies while also sharing resources with other hospitals and agencies when needed during the pandemic,” said Jennifer Nichols, laboratory finance manager for Dayton Children’s.

Dayton Children’s Hospital was selected by the State of Ohio to deliver regional laboratory care during the pandemic. The hospital also partnered with the Greater Dayton Area Hospital Association (GDAHA) to provide laboratory equipment and testing kits to various hospitals across nine different counties. In addition, Dayton Children’s Hospital opened three, drive-through COVID-19 testing sites for children and adults, and enacted a patient surge plan to care for adult patients when other hospitals did not have available beds.

“Our lab team truly went above and beyond to make sure we could provide all the testing our patients needed, as well as offer testing resources to the community as a whole,” said Melanie Wilson, senior director of laboratory services and medical imaging for Dayton Children’s.

“The keys to navigating these tough times were collaboration and communication,” said Wilson. “Through it all, our supply chain never let us down.”

 Learn more about Medline’s laboratory solutions.

SourceMedline

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version